-
Analysts Digest Biogen's Alzheimer's Disappointment: 'There Isn't Much To Be Excited About'
Friday, March 22, 2019 - 1:30pm | 595Read More...Biogen Inc (NASDAQ: BIIB) shares plunged nearly 30 percent Thursday after, along with development partner Eisai Co., Ltd (OTC: ESALY) announced the decision to scrap two late-stage trials evaluating their Alzheimer's candidate aducanumab. The Analysts Mizuho Securities analyst Salim Syed...
-
Biogen Plunges 25% After Company Discontinues Alzheimer's Drug Study
Thursday, March 21, 2019 - 8:17am | 348Read More...Shares of neuroscience company Biogen Inc (NASDAQ: BIIB) lost more than 25 percent Thursday morning after the company said it will discontinue an ongoing Alzheimer's drug study. What Happened Biogen and its partner Japan-based Eisai said they will discontinue an ongoing global Phase 3...
-
After Biogen's Alzheimer's Update, Wall Street Reacts
Friday, July 6, 2018 - 1:27pm | 643Read More...Biogen Inc (NASDAQ: BIIB) and its Japanese partner Eisai disclosed encouraging results from an 18-month Phase 2 study of its Alzheimer's therapy BAN2401. Here's how some Street analysts reacted to the news. The Analysts Raymond James' Laura Chico maintained a Market...
-
Argus Downgrades Biogen On Trial Delays, Competition In MS, Alzheimer's Drugs
Friday, February 16, 2018 - 10:37am | 360Read More...Biogen Inc (NASDAQ: BIIB) tumbled 8 percent Wednesday after announcing a cohort expansion for its aducanumab Alzheimer’s trials — a change certain to delay results. The news, coupled with expected sales declines, has converted one analyst from an advocate to an observer. The Rating...
-
Biogen's Best-In-Class R&D Earn Makes It A Buy
Tuesday, October 17, 2017 - 11:35am | 363Read More...Analysts at Stifel turned bullish on Biogen Inc (NASDAQ: BIIB) for four key reasons. The firm's Thomas Shrader upgrades Biogen's stock from Hold to Buy with a price target boosted from $300 to $415. First, there have been no news reports on the "gigantic" aducanumab phase 3 trial, which started in...
-
Biogen's Core Business Impresses While Potential Alzheimer's Catalyst Looms
Thursday, October 5, 2017 - 10:54am | 331Read More...Analysts at Morgan Stanley turned bullish on Biogen Inc (NASDAQ: BIIB) as the company's phase 3 Alzheimer's catalyst could "make all its potential issues disappear." The firm's Matthew Harrison upgraded Biogen's stock rating from Equal-Weight to Overweight with a price target boosted from $311 to $...
-
19% Upside Predicted For Biogen, Goldman Upgrades On Strength Of Alzheimer's Drug
Wednesday, July 26, 2017 - 10:09am | 350Read More...Goldman Sachs upgraded Biogen Inc (NASDAQ: BIIB) from Neutral to Buy and raised its price target to $338 on the strength of the pharmaceutical company’s Alzheimer’s drug, Aducanumab. Analyst Terence Flynn said the drug “could now be one of the first disease-modifying drugs to...
-
Taking A Clinical Road Less Traveled: Neurotrope Hopes To Succeed In Alzheimer's Where Competitors Fail
Monday, January 30, 2017 - 3:04pm | 1344Read More...Alzheimer's has proven to be one of the most stubborn diseases known to modern medicine. An incurable, devastating illness that inspires frustration — even anger — against and from the scientific community itself, which has failed to develop new, effective therapies. Susanne...
-
Reasons To Be Optimistic On Biogen's Alzheimer's Treatment Prospects
Friday, November 25, 2016 - 11:12am | 353Read More...H.C. Wainwright said it is not surprised by Eli Lilly and Co (NYSE: LLY)’s announcement of solanezumab failing to slow the cognitive decline in Alzheimer’s Disease patients. The news is also said to be a negative for Biogen Inc (NASDAQ: BIIB), which is testing its own Alzheimer's...
-
Experts React To Concerning Alzheimer's News From Eli Lilly
Friday, November 25, 2016 - 9:39am | 445Read More...Eli Lilly and Co (NYSE: LLY) fell steeply Wednesday after it announced that its Alzheimer's disease treatment candidate solanezumab didn't meet the primary endpoint in a late-stage clinical trial dubbed EXPEDITION3. In a sympathy move, Biogen Inc (NASDAQ: BIIB) also traded notably lower. Is the...
-
Biotech Conference Suggests Tempering Expectations For Eli Lilly Drug
Tuesday, February 16, 2016 - 2:47pm | 307Read More...According to a recent note out by Leerink, investor expectations toward one of Eli Lilly and Co (NYSE: LLY)'s drugs may need to be readjusted. During a biotech conference, panelists provided updates on Lilly's solanezumab, telling investors that the drug, while likely to be approved,...
-
Wall Street Mixed On Biogen Before Earnings
Thursday, July 23, 2015 - 5:39pm | 729Read More...Shares of Biogen Inc (NASDAQ: BIIB) fell 1.71 percent on Thursday's trading, ahead of the announcement of the company’s second quarter financial results, scheduled for before the market opens on Friday. According to Estimize, the Street is expecting to see 17 percent year-over-year growth...
-
Piper Jaffray On Biogen Downgrade: '6 MG Data Does Not Inspire Confidence…Even More Speculative Than Before'
Wednesday, July 22, 2015 - 11:29am | 478Read More...In a report published Wednesday, Piper Jaffray analyst Joshua Schimmer downgraded shares of Biogen Inc (NASDAQ: BIIB) to Neutral from Buy with a price target lowered to $410 from a previous $485 following the company's results for the 6mg Aducanumab arm in its P2 study for Alzheimer's....
-
Disappointing Drug News Sends Biogen And XOMA Shares Down
Wednesday, July 22, 2015 - 10:34am | 560Read More...Shares of Biogen Inc (NASDAQ: BIIB) were trading lower by more than 3 percent Wednesday morning after the company reported mixed results in a Phase 1 Alzheimer's study in which a 6MG dose failed to significantly slow mental decline. "We are encouraged by these new results, which...
-
RBC Says Biogen Can Move 10% After BIIB-037 Data Is Revealed
Friday, July 10, 2015 - 12:04pm | 317Read More...Biogen Inc (NASDAQ: BIIB) is down 3 percent on Friday after commentary from Cowen. Analyst Eric Schmidt suggested investors not play the company's upcoming AAIC data reveal centered on Aducanumab, scheduled for July 22, due to a lack of conviction. It didn't take long for RBC's...
